Dupilumab-associated ocular surface disease in atopic dermatitis patients: clinical characteristics, ophthalmic treatment response, and conjunctival goblet cell analysis.

Roselie E Achten Judith L ThijsMarlot van der WalChantal van LuijkMarlies de GraafDaphne S BakkerJoke de BoerFemke van WijkMarjolein de Bruin-Weller

Published in: Allergy (2023)

OSD is common in moderate-to-severe AD patients before starting dupilumab. During treatment with dupilumab DAOSD severity improves with early ophthalmic treatment. The decrease in percentage of CK19-CD45-MUC5AC+ cells during dupilumab treatment suggests an impairment of the GC function due to dupilumab treatment.

Keyphrases

atopic dermatitis
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
single cell
patient reported outcomes
combination therapy
cell proliferation
cell therapy
mass spectrometry
high resolution
bone marrow
cell death
drug induced
solid phase extraction